Thyrotropin-releasing hormone stimulates the release of melanotropin from frog neurointermediate lobes in vitro

The hypothalamus of Amphibia contains large amounts of tripeptide P-Glu-His-Pro-NH₂ (mammalian thyrotropin-releasing hormone, TRH). However, synthetic TRH is unable to stimulate thyrotropin release from frog pituitary gland. The recent discovery of TRH in the skin of the frog suggests a possible role of this peptide in skin-colour adaptation. Thus we have investigated the role of TRH upon melanotropin (α-MSH) release from perifused frog neurointermediate lobes. A dose related increase in α-MSH release was observed when TRH was added to the perifusion medium. Half-maximum stimulation occurred with the 1 × 10^?8M dose. Theophylline at a dose of 2 × 10^?3M strongly enhanced TRH-induced α-MSH release, indicating that cyclic AMP may be the second messenger. α-MSH releade was not modified by crude homogenates of rat hypothalamus but was significantly reduced when the hypothalamus extracts were preincubated with specific TRH antibodies. As far is known, these results provide the first evidence that P-Glu-His-Pro-NH₂ stimulates the release of α-MSH from frog neurointermediate lobes $\text{in vitro}$. The present findings suggest a possible feedback loop between skin TRH and pituitary MSH in Amphibia.     

Isolation, structural elucidation and synthesis of a tetradecapeptide with in vitro ACTH-releasing activity corresponding to residues 33-46 of the alpha-chain of porcine hemoglobin.

A peptide found in acetic acid extracts of porcine hypothalami and capable of stimulating the release of ACTH in vitro was isolated in pure state, structurally identified as Phe-Leu-Gly-Phe-Pro-Thr-Thr-Lys-Thr-Tyr-Pre-Pro-His-Phe and synthesized. This tetradecapeptide, which corresponds to amino acid residues no. 33–46 in the sequence of the α-chain of porcine hemoglobin, probably represents an artefact of extraction or isolation procedures. Since this peptide stimulates ACTH release from rat pituitary fragments and from monolayer cultures of pituitary cells, but not $\text{in vivo}$, caution must be exercised in interpreting the results of $\text{in vitro}$ assays for corticotropin releasing factor.     

Occurrence of a new melanocyte stimulating hormone in the salmon pituitary gland

A new melanocyte stimulating hormone has been identified in the pituitary of the teleost, $\text{Oncorhynchus keta}$ (chum salmon). The newly isolated MSH like peptide is a heptadeca peptide, which differs in size from salmon α-MSH (13 residues) and β-MSH I and II (17 residues each). The structural determination, however, revealed that it is similar to but distinct form α-MSH, with following amino acid sequence, Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Ile-Gly-His-OH. This peptide, named α-MSH II is the third line of evidence in the salmon that the teleost pituitary gland secretes two different forms of processed hormones, for which the precursor molecules are coded on two separate genes.     

The influence of beta-LPH fragments on alpha-MSH release: the involvement of a dopaminergic system

β-Endorphin was able to enhance plasma α-MSH levels in rats after intracerebroventricular injection. This effect could be inhibited by naloxone or by removing tyrosine from position 61 of the peptide. Neither α- and γ-endorphin nor their des-tyrosine analogs appeared to be able to modify plasma α-MSH levels. The stimulating effect of β-endorphin on plasma α-MSH levels could be completely blocked by a simultaneous injection of apomorphine, in an amount in which apomorphine itself had no effect on α-MSH levels in plasma. A single injection of haloperidol increased plasma α-MSH levels in a dose related manner. A dose of haloperidol, which caused an apomorphine antagonizable increase in plasma α-MSH, did not modify β-endorphin elevated α-MSH levels. A high concentration of haloperidol was able to stimulate the basal release of α-MSH from isolated pituitaries $\text{in bitro}$, whereas β-endorphin appeared to be inactive in this respect.These observations indicate a central opiate receptor-mediated influence of β-endorphin on α-MSH release and the possible involvement of a dopaminergic system, mediating the β-endorphin effect.     

Effects of cholinergic drugs on growth hormone release

Acetylcholine and the cholinergic agonists, pilocarpine and physostigmine, increased GH release $\text{in}$$\text{vivo}$. The increase in GH release by pilocarpine was reversed by concurrent administration of the cholinergic receptor blocker, atropine, whereas atropine alone did not alter serum GH concentrations. Cholinergic stimulation of GH release appears to be partially mediated through a catecholaminergic system since the response was partially inhibited by pimozide, a dopamine receptor blocker, or phentolamine, an α-adrenergic receptor blocker. The cholinergic system may function physiologically to help regulate GH release.     

Somatocrinin,growth hormone releasing factor,stimulates secretion of growth hormone in anesthetized rats

The synthetic replicate of a 44 amino acid peptide isolated from a human pancreatic tumor which had caused acromegaly possesses high specific activity to release growth hormone (GH) in anesthetized male rats. The GH secretion induced by this peptide is dose-dependent from 50 ng to 1 μg, with plasma GH concentrations increasing more than 10-fold within 5 min of iv administration at the higher doses. Two enzymatic degradation products of the 44 residue peptide were also isolated and consist of the first 37 and 40 amino acids. All three peptides appear to possess similar potency, on a molar basis, $\text{in}\text{vivo}$, contrary to $\text{in}\text{vitro}$ results. The specificity of these peptides on GH release was shown by their failure to alter plasma concentrations of prolactin (PRL), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and corticosterone. Based on these $\text{in}\text{vivo}$ results, the three peptides with serve as powerful tools with which to investigate the mechanisms of GH secretion.     

Direct in vitro stimulation of pituitary LH release by alpha melanocyte stimulating hormone

The present $\text{in vitro}$ superfusion study demonstrates that synthetic α-MSH acts at the pituitary level, independent of the hypothalamus, to increase the release of LH in male but not in female rats.     

Synthesis and biological activity of four gamma-melanotropin peptides derived from the cryuptic region of the adrenocorticotropin/beta-lipotropin precursor.

A third melanotropin coding fragment named γ-MSH was discovered by Nakanishi et al (Nature $\text{278}$, 423–427 (1979)) in the cryptic region outside the portion coding for ACTH and β-LPH in the ACTH/β-LPH precursor mRNA isolated from the intermediate lobe of bovine pituitary. Four possible γ-MSH peptides derived from this coding fragment were synthesized by solid-phase methodology and their bioactivity determined in an $\text{in vitro}$ MSH assay as well as the anterior pituitary primary culture assay. Relative to α-MSH, the melanotropic activities of Ac-γ₁-MSH, γ₁-MSH, γ₂-MSH and γ₃-MSH are 7.3 × 10^?4, 3.3 × 10^?5, 1.4 × 10^?4 and 4.6 × 10^?7 respectively. None of these γ-MSH peptides releases LH, FSH, PRL, GH and TSH in the pituitary culture medium at a dose as high as 100 ng per dish.     

Stimulatory effect of prostaglandin E1 on thyroliberin-induced α-melanotropin release from perifused neuro-intermediate lobes of frog pituitary gland

A possible direct effect of prostaglandins on α-melanotropin (α-MSH) release at the level of the intermediate lobe of the frog pituitary was investigated $\text{in vitro}$ using a perifusion system technique. The effect of prostaglandins was studied on both spontaneous and TRH-stimulated α-MSH secretion. No significant effect of PGE₁, PGE₂, PGF_1α or PGF_2α on basal release of α-MSH could be detected. Indomethacin did not alter the α-MSH release induced by TRH. Conversely a significant increase in TRH-induced α-MSH secretion was observed in the presence of 1 x 10^?6M PGE₁. This magnifying effect was directly related to the concentration of TRH for doses ranging from 1 x 10^?8M to 1 x 10^?6M.     

Cholecystokinin octapeptide releases growth hormone from the pituitary in vitro

Cholecystokinin-octapeptide (CCK-8)(10^?6 to 10^?8M) produced a marked increase in growth hormone (GH) release from incubated rat anterior pituitary quarters and from cultured GH₃ pituitary tumor cells. Although several CCK-8 analogues also caused GH release, bombesin, secretin and pancreatic polypeptide had no effect on GH secretion $\text{in vitro}$. In the GH₃ cell line, CCK-8 (10^?7M) reversed the inhibitory effect of somatostatin (10^?5M) on GH release. As CCK immunoreactivity has been demonstrated to be present in the hypothalamus, these results suggest that CCK-8 may be a physiologically important growth hormone releasing factor.     

Identification and purification of factor B-GHRH from hypothalami which releases growth hormone

Exploratory purifications and assays of fractions for release of growth hormone (GH) revealed two separable entities each of which unambiguously released GH by radioimmunoassay. They are provisionally designated factor A-GHRH and factor B-GHRH until they are chemically and biologically characterized. After initial steps of isolation from porcine hypothalami, factor B-GHRH was extensively purified by stepwise chromatography using Bio-Gel P-2, Sephadex LH-20, Sephadex G-25 with a partition system of acetic acid-butanol-pyridine, DEAE-Sephadex A-25, and Bio-Gel CM-2. Assays showed that certain fractions were active, $\text{in vitro}$, at levels of $\text{ca}$. 15 μg. Factor B-GHRH is inhibited by somatostatin.     

Rat posterior lobe modulates growth hormone release in vivo and in vitro

Electrical stimulation of hypophysical posterior lobes $\text{in vivo}$ evokes a significant decrease of plasma growth hormones (GH) and an increase of plasma corticotropin (ACTH) concentrations. Electrical stimulation of posterior lobes $\text{in vitro}$ evokes the simultaneous release of GH inhibiting factor(s) (GHRIF) and ACTH releasing factor(s) (CRF) into the medium. Pretreatment of media with thioglycolate abolishes the CRF and GHRIF activity, but reveals GH releasing factor(s) (GHRF). Median eminence extracts and vasopressin have potent GHRF and CRF activity. Vasopressin may account fully for the CRF and partially for GHRF activity. Results suggest that hypothalamo-neurohypophysical axons release GHRIF, vasopressin and possibly a GHRF into a portal circulation to modulate the secretion of GH and ACTH.     

Trypsin inhibitory activity of a polypeptide isolated from red kidney beans, that also enhances lymphocyte stimulation.

A polypeptide isolated from red kidney beans, $\text{Phaseolus}\text{vulgaris}$, which has previously been shown to stimulate RNA synthesis in cultures of mouse spleen lymphocytes and plasmolyzed $\text{E.}\text{coli}$, is here shown to be a potent inhibitor of trypsin and α-chymotrypsin. This polypeptide is compared with commercially available trypsin inhibitors with regard to their capacity to inhibit some proteolytic enzymes and to stimulate $\text{in}\text{vitro}$ cultures of lymphocytes. Similar to FV the lima been trypsin inhibitor was found to possess a stimulating effect on the RNA as well as the DNA synthesis in lymphocyte cultures.     

Lipotropin: precursor to two biologically active peptides.

Lipotropin appears to be the common precursor to β-MSH, a peptide with lipolytic activity, and C-Fragment, a peptide with potent opiate activity. The product formed is determined by the specificity of the activating enzymes.The amino acid sequence of β-MSH, the 18 residue melanocyte stimulating hormone, is contained within the central region of lipotropin (LPH), a 91 residue polypeptide. On this basis Li and his colleagues¹ suggested that LPH might be the prohormone of β-MSH. Bertagna, Lis and Gilardeau², on the other hand, were unable to demonstrate conversion of LPH to β-MSH $\text{in vitro}$ using pulse labelling techniques. If LPH is the precursor of β-MSH, formation of the hormone should be accompanied by release of the contiguous fragments of the prohormone and the fragments remain in the secretory particle of the gland. To obtain evidence on the biosynthetic origin of β-MSH, we have isolated peptides from pituitary in a search for the N- and C-fragments of the prohormone.     

Absence of 5′-nucleotidase in porcine polymorphonuclear leucocyte membranes

A fraction enriched in plasma membranes from porcine polymorphonuclear leucocytes, isolated by sucrose density centrifugation was shown to possess considerable AMP hydrolysing activity (150 nmol/min per mg protein). However all of this activity could be inhibited using excess $\text{p-}\text{nitrophenyl}$ phosphate in the incubation medium. Furthermore the hydrolysis of AMP by the membrane was unaffected by the 5′-nucleotidase inhibitor α,β-methyleneadenosine diphosphate and by the lectin concanavalin A, another potent inhibitor of 5′-nucleotidase. An antibody against mouse liver 5′-nucleotidase also did not inhibit the activity. These results suggest that the hydrolysis of AMP by porcine polymorph membranes is not accomplished by a specific 5′-nucleotidase and the necessity for distinguishing between true 5′-nucleotidase and non-specific phosphatase activity is discussed.     

Regulation of canine renal vesicle Pi transport by growth hormone and parathyroid hormone

Renal phosphate (P_i) reabsorption is increased by growth hormone (GH) and decreased by parathyroid hormone (PTH). Na⁺-stimulated P_i transport across the brush border membrane of the proximal tubule is the initial step in the process of P_i reabsorption. To determine whether changes in P_i reabsorption induced by GH or PTH are accompanied by changes in brush border membrane Na⁺-gradient-stimulated P_i transport, we examined the effect of in vivo GH and PTH administration and thyroparathyroidectomy on P_i transport by isolated brush border membrane vesicles prepared from canine kidney. In experiments in which the effect of PTH administration was examined, the same animal provided the control kidney (before PTH administration) and the experimental kidney (after PTH administration). The Na⁺-gradient P_i overshoot in vesicles isolated from normal, GH-treated and thyroparathyroidectomized dogs was increased after in vivo PTH administration. GH administration and thyroparathyroidectomy increased the height of the overshoot compared to normal. PTH administration decreased the apparent $\text{V}$ value by 44% in vesicles from normal animals. The apparent $\text{V}$ value was increased, compared to normal, by GH (34%) and thyroparathyroidectomy (57%). PTH administration decreased the apparent $\text{V}$ in both the latter groups. GH administration to thyroparathyroidectomized dogs further increased the apparent $\text{V}$. Changes in the apparent $\text{V}$ paralleled changes in P_i reabsorption in vivo induced by experimental manipulations. We conclude that changes in renal P_i reabsorption induced by GH were like those induced by PTH, accompanied by changes in the Na⁺-stimulated P_i transport system in the renal brush border membrane, and that the effect of PTH on vesicular P_i transport in GH-treated dogs did not differ from the effect on vesicles from normal animals.     

Differential distribution of molecular forms of cholecystokinin in human and porcine small intestinal mucosa

To examine the distribution of cholecystokinins (CCKs) along the small intestine we examined the nature of CCKs in samples of jejunum, mid-intestine and ileum from human and porcine intestine. CCKs in intestinal mucosa were extracted by boiling in both neutral and acid conditions, and subjected to high pressure liquid chromatography (HPLC) to separate the forms of CCK followed by radioimmunoassay of separate fractions.In neutral extracts of human intestine CCK immunoreactivity totalled 119.4, 22.9 and <1 ng/g in jejunum, mid-intestine and ileum, whilst in acid extracts the corresponding values were 65.3, 47.4 and <1 ng/g. Amounts of CCK extracted from porcine mucosa were of similar magnitude. In neutral extracts material co-chromatographing on HPLC with synthetic porcine CCK 8 predominated, whilst in acid extracts material co-chromatographing with CCKs $\text{33}\text{39}$ was the major form. These forms of human and porcine CCKs extracted from the mucosa behaved similarly to CCK 8 and CCK $\text{33}\text{39}$ standards on HPLC, in the radioimmunoassay and on molecular exclusion chromatography — suggesting marked similarity of the CCKs in the two species. In both species there was a marked change in the ratios of CCK 8: CCK $\text{33}\text{39}$ down the intestine from 1 : 0.8 in human jejunum to 1 : 5.6 in mid-intestine and from 1 : 1.5 in porcine jejunum to 1 : 5.8 in mid-intestine. These observations may explain the changing patterns of CCKs in circulation with time after ingestion of a fat meal and the greater impairment of CCK 8 than CCK $\text{33}\text{39}$ release observed in coeliac disease.     

Sex pheromone of the potato tuberworm moth, Phthorimaea operculella.

A compound was isolated from female $\text{Phthorimaea operculella}$ (Lepidoptera: Gelechiidae) abdominal tip extracts and identified as $\text{trans}$-4, $\text{cis}$-7-tridecadienyl acetate. The synthetic compound elicits male $\text{P. operculella}$ wing fanning and upwind orientation in the laboratory, and is attractive to males in the field. The corresponding alcohol also appeared to be present in the female extracts, but this compound was not found to increase male responses in the laboratory or the field. Another EAG active component was isolated but not identified.